- Home
- SNDX vs BCSF Comparison
SNDX vs BCSF Comparison
Compare SNDX & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- BCSF
- Stock Information
- Founded
- SNDX 2005
- BCSF 2015
- Country
- SNDX United States
- BCSF United States
- Employees
- SNDX N/A
- BCSF N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- SNDX Health Care
- BCSF Finance
- Exchange
- SNDX Nasdaq
- BCSF Nasdaq
- Market Cap
- SNDX 1.1B
- BCSF 983.4M
- IPO Year
- SNDX 2016
- BCSF 2018
- Fundamental
- Price
- SNDX $15.04
- BCSF $14.56
- Analyst Decision
- SNDX Strong Buy
- BCSF Buy
- Analyst Count
- SNDX 10
- BCSF 2
- Target Price
- SNDX $38.40
- BCSF $16.50
- AVG Volume (30 Days)
- SNDX 2.0M
- BCSF 271.2K
- Earning Date
- SNDX 11-04-2025
- BCSF 11-04-2025
- Dividend Yield
- SNDX N/A
- BCSF 12.35%
- EPS Growth
- SNDX N/A
- BCSF N/A
- EPS
- SNDX N/A
- BCSF 1.66
- Revenue
- SNDX $77,933,000.00
- BCSF $283,687,000.00
- Revenue This Year
- SNDX $585.73
- BCSF N/A
- Revenue Next Year
- SNDX $94.17
- BCSF N/A
- P/E Ratio
- SNDX N/A
- BCSF $8.77
- Revenue Growth
- SNDX 2126.66
- BCSF N/A
- 52 Week Low
- SNDX $8.58
- BCSF $13.20
- 52 Week High
- SNDX $22.50
- BCSF $19.21
- Technical
- Relative Strength Index (RSI)
- SNDX 49.91
- BCSF 29.79
- Support Level
- SNDX $15.71
- BCSF $15.45
- Resistance Level
- SNDX $16.50
- BCSF $15.75
- Average True Range (ATR)
- SNDX 0.82
- BCSF 0.22
- MACD
- SNDX -0.31
- BCSF -0.10
- Stochastic Oscillator
- SNDX 2.44
- BCSF 3.40
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.